[Calcimimetic drugs in nondialyzed patients].
With the progression of chronic kidney disease (CKD) possibilities of regulation of parathyroid hormone (PTH) secretion also decrease. Calcimimetics offer the possibility of direct influence on pathogenic mechanisms of secondary hyperparathyroidism in the early stages of CKD. Type II calcimimetic drugs inhibit PTH secretion by sensitizing the parathyroid calcium receptor to extracellular calcium. They found clinical application of in disease states running from hyperparathyroidism. The paper discusses the application of calcimimetic drug type II--cinacalcet--in the treatment of secondary hyperparathyroidism in patients with CKD and patients with hyperparathyroidism surviving renal transplantation. Cinacalcet oral administration (15-180 mg/day) significantly reduces plasma PTH concentration (> or = 30% as compared to baseline values) at a relatively low side effects (hypocalcemia, hyperphosphatemia, gastrointestinal symptoms). In patients after renal transplantation cinacalcet, according to the majority of data, has no effect on graft function and effectively helps in the treatment of persistent hyperparathyroidism, especially running with hypercalcemia.
Grzegorzewska
Alicja E
AE
Uniwersytet Medyczny w Poznaniu, Katedra i Klinika Nefrologii, Transplantologii i Chorób Wewnetrznych. alicja_grzegorzewska@yahoo.com
D002908:Chronic Disease; D000069449:Cinacalcet; D018450:Disease Progression; D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy* / Q000209:etiology; D007674:Kidney Diseases / Q000150:complications* / Q000378:metabolism* / Q000628:therapy; D016030:Kidney Transplantation; D009281:Naphthalenes / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000097:blood / Q000378:metabolism*
D009281:Naphthalenes; D010281:Parathyroid Hormone; D000069449:Cinacalcet